Table 1 Clinical and pathological characteristics of the patients grouped by TIL density
CD3+ TIL n = 99 | CD8+ TIL n = 107 | CD45RO+ TIL n = 110 | |||||||
|---|---|---|---|---|---|---|---|---|---|
Characteristics | low | high | P-value | low | high | P-value | low | high | P-value |
Total number of patients | 42 (42.4%) | 57 (57.6%) | 50 (46.7%) | 57 (53.3%) | 17 (15.5%) | 93 (84.5%) | |||
Gender | 0.453 | 1.0 | 0.607 | ||||||
male | 38 (38.4%) | 54 (54.5%) | 46 (43.0%) | 53 (49.5%) | 15 (13.6%) | 87 (79.1%) | |||
female | 4 (4.0%) | 3 (3.0%) | 4 (3.7%) | 4 (3.7%) | 2 (1.8%) | 6 (5.5%) | |||
Tumour stage | 0.298 | 0.688 | 0.353 | ||||||
pT1 | 15 (15.3%) | 26 (26.5%) | 20 (18.9%) | 25 (23.6%) | 6 (5.5%) | 42 (38.5%) | |||
pT2 | 7 (7.1%) | 12 (12.2%) | 9 (8.5%) | 12 (11.3%) | 2 (1.8%) | 18 (16.5%) | |||
pT3 | 20 (20.4%) | 18 (18.4%) | 21 (19.8%) | 19 (17.9%) | 9 (8.3%) | 32 (29.4%) | |||
Lymph node metastasis | 0.025 | 0.440 | 0.065 | ||||||
pN0 | 17 (17.3%) | 35 (35.7%) | 26 (24.5%) | 31 (29.2%) | 6 (5.5%) | 54 (49.5%) | |||
pN1 | 25 (25.5%) | 21 (21.4%) | 24 (22.6%) | 25 (23.6%) | 11 (10.1%) | 38 (34.9%) | |||
Distant metastasis | 0.212 | 0.428 | 0.108 | ||||||
M0 | 37 (37.8%) | 53 (54.1%) | 45 (42.5%) | 52 (49.1%) | 14 (12.8%) | 87 (79.8%) | |||
M1 | 5 (5.1%) | 3 (3.1%) | 5 (4.7%) | 4 (3.8%) | 3 (2.8%) | 5 (4.6%) | |||
Residual tumour | 0.070 | 0.276 | 0.125 | ||||||
R0 | 33 (34.4%) | 51 (53.1%) | 41 (39.4%) | 51 (49.0%) | 13 (12.1%) | 81 (75.7%) | |||
R1 | 8 (8.3%) | 4 (4.2%) | 7 (6.7%) | 5 (4.8%) | 4 (3.7%) | 9 (8.4%) | |||
Grading | 0.273 | 0.696 | 0.091 | ||||||
G1 | 0 (0.0%) | 2 (2.1%) | 2 (1.9%) | 1 (1.0%) | 0 (0.0%) | 5 (4.6%) | |||
G2 | 17 (17.5%) | 27 (27.8%) | 20 (19.0%) | 26 (24.8%) | 4 (3.7%) | 42 (38.9%) | |||
G3 | 25 (25.8%) | 26 (26.8%) | 27 (25.7%) | 29 (27.6%) | 13 (12.0%) | 44 (40.7%) | |||
UICC classification | 0.086 | 0.776 | 0.156 | ||||||
I | 11 (11.2%) | 24 (24.5%) | 16 (15.1%) | 23 (21.7%) | 4 (3.7%) | 38 (34.9%) | |||
II | 11 (11.2%) | 19 (19.4%) | 16 (15.1%) | 17 (16.0%) | 4 (3.7%) | 28 (25.7%) | |||
III | 15 (15.3%) | 10 (10.2%) | 14 (13.2%) | 12 (11.3%) | 6 (5.5%) | 21 (19.3%) | |||
IV | 5 (5.1%) | 3 (3.1%) | 4 (3.8%) | 4 (3.8%) | 3 (2.8%) | 5 (4.6%) | |||
Recurrence of disease | 0.005 | 0.209 | 0.018 | ||||||
No | 13 (13.3%) | 33 (33.7%) | 21 (19.8%) | 30 (28.3%) | 4 (3.7%) | 50 (45.9%) | |||
Yes | 29 (29.6%) | 23 (23.5%) | 28 (26.4%) | 27 (25.5%) | 13 (11.9%) | 42 (38.5%) | |||